Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis

Early intervention with high-efficacy disease-modifying therapy (HE DMT) may be the best strategy to delay irreversible neurological damage and progression of multiple sclerosis (MS). In European healthcare systems, however, patient access to HE DMTs in MS is often restricted to later stages of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Filippi, Massimo, Danesi, Romano, Derfuss, Tobias, Duddy, Martin, Gallo, Paolo, Gold, Ralf, Havrdová, Eva Kubala, Kornek, Barbara, Saccà, Francesco, Tintoré, Mar, Weber, Jörg, Trojano, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Short Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501364/
https://www.ncbi.nlm.nih.gov/pubmed/34626224
http://dx.doi.org/10.1007/s00415-021-10836-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501364/
https://www.ncbi.nlm.nih.gov/pubmed/34626224
http://dx.doi.org/10.1007/s00415-021-10836-8

Ejemplares similares